GFAP and Alzheimer disease: Notably, RSG reduced glial fibrillary acidic protein (GFAP) staining in a 10-month-old triple transgenic (3xTg)-AD mouse model following the dietary administration of 50 mg/kg of RSG for 4 months and diminished the astroglial inflammatory reaction and GFAP intensity in a 4-month-old 2xTg-mouse model following 3 months of RSG administration [15,16].